Compare Summit Therapeutics Inc (SMMT) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Summit Therapeutics Inc trades at $17.6 (market cap $13.71B), while Consumer Discretionary Select Sector SPDR Fund trades at $112.69 (market cap $21.89B). The key difference: Consumer Discretionary Select Sector SPDR Fund is the larger of the two by market cap, and Summit Therapeutics Inc is more actively traded (6,173,057 versus 5,690,342). Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Consumer Discretionary Select Sector SPDR Fund for 114 Days on average.
| SMMT | XLY | |
|---|---|---|
Market Cap | $13.71B | $21.89B |
Volume | 6,173,057 | 5,690,342 |
Sector | Health | — |
52-Week High | $26.38 | $124.52 |
52-Week Low | $12.43 | $105.64 |
Typical Hold Time | 16 Days | 114 Days |
Enterprise Value | $13.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
XLY trades at $112.85, up 1.34% with a bullish technical signal despite mixed momentum indicators. The ETF shows strong analyst consensus with 100% buy ratings but faces fundamental data gaps. Recent news highlights consumer discretionary sector challenges, with XLY underperforming staples by 13% year-to-date amid inflation pressures and selective consumer spending trends.
Outlook remains cautiously optimistic given analyst support, but persistent underperformance versus the S&P 500 and inflation risks warrant monitoring. The 'funflation' trend and potential holiday sales growth offer upside catalysts, though sector volatility and Tesla's weighting drag present near-term headwinds for discretionary exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
